Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
European Journal of Cancer & Clinical Oncology|February 1, 1989
Carrier mediated action of platinum complexes on estrogen receptor positive tumorsN Knebel, C D Schiller, M R Schneider, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1982
3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compoundG Kranzfelder, R W Hartmann, E von Angerer, et al.Journal of Medicinal Chemistry|September 1, 1982
1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting propertiesM R Schneider, E von Angerer, H Schönenberger, et al.Journal of Medicinal Chemistry|September 18, 1992
6-Alkyl-12-formylindolo[2,1-a]isoquinolines. Syntheses, estrogen receptor binding affinities, and stereospecific cytostatic activityT Polossek, R Ambros, S von Angerer, et al.Journal of Medicinal Chemistry|October 1, 1984
Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinomaB Wappes, M Jennerwein, E von Angerer, et al.The Journal of Steroid Biochemistry and Molecular Biology|May 1, 1992
Estrogen platinum-diamine complexes: preparation of a non-steroidal estrogen platinum-diamine complex labeled with platinum-191 and a study of its binding to the estrogen receptor in vitro and its tissue distribution in vivoJ P DiZio, K E Carlson, C J Bannochie, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1981
The tumor-inhibiting effect of diethylstilbestrol-3,4-oxideM R Schneider, G Kranzfelder, E von Angerer, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1984
The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexesB Wappes, M Jennerwein, E von Angerer, et al.British Journal of Cancer|March 1, 1990
Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee studyR C Stein, M Dowsett, D C Cunningham, et al.Pageof 6